Estrogen plays a key role in maintaining the morphology and function of the efferent ductules. We previously demonstrated that the antiestrogen fulvestrant markedly affected gene expression in the rat efferent ductules. The mechanism of fulvestrant action to modulate gene expression may involve not only the blockade of ESR1 and ESR2 estrogen receptors, but also the activation of ESR1 and ESR2 when the receptors are tethered to AP-1 or SP1 transcription factors, or the activation of the G protein-coupled estrogen receptor 1. We therefore compared the effects of two strategies to interfere with estrogen action in the rat efferent ductules: treatment with fulvestrant or with the aromatase inhibitor anastrozole. Whereas fulvestrant markedly increased Mmp7 and Spp1, and reduced Nptx1 mRNA levels, no changes were observed with anastrozole. Fulvestrant caused changes in epithelial morphology that were not seen with anastrozole. Fulvestrant shifted MMP7 immunolocalization in the epithelial cells from the supranuclear to the apical region; this effect was less pronounced with anastrozole. In vitro studies of 35 S-methionine incorporation showed that protein release was increased, whereas tissue protein content in the efferent ductules of fulvestrant-treated rats was decreased. Although fulvestrant markedly affected gene expression, no changes were observed on AP-1 and SP1 DNA-binding activity. The blockade of ESRs seems to be the major reason explaining the differences between both treatments. At least some of the effects of fulvestrant appear to result from compensatory mechanisms activated by the dramatic changes caused by ESR1 blockade. estradiol receptor, gene regulation, male reproductive tract
INTRODUCTION
Estrogens are important regulators of development, differentiation, and growth of the male reproductive system [1] . In the male reproductive tract, estrogen is mainly synthesized by Sertoli, Leydig, and germ cells, which contain the aromatase cytochrome P450 that catalyses the conversion of testosterone to estradiol [2] [3] [4] . Estrogen may also be locally synthesized in human and rat epididymis, and in human efferent ductules, wherein aromatase has also been detected [5, 6] .
Estrogen modulates gene transcription, and the classical mechanism of estrogen action involves the interaction of the hormone with the estrogen receptors ESR1 and ESR2, which bind directly to palindromic target DNA sequences, the estrogen responsive elements (EREs) [reviewed in 7, 8] . Estrogen receptors may also modulate gene transcription without binding to ERE, but through protein-protein interaction with other transcription factors, such as AP-1 and SP1 [9] [10] [11] [12] [13] . In addition, ESRs and the recently described G protein-coupled estrogen receptor (GPER) can also mediate rapid signaling mechanisms after estrogen stimulation, and these mechanisms may ultimately affect gene transcription [reviewed in [14] [15] [16] [17] [18] [19] .
The efferent ductules present the highest concentration of estrogen receptors in the male reproductive system [20] , and a genetic disruption of the estrogen receptor Esr1 causes infertility and dramatic changes in the morphology and function of this tissue [21] [22] [23] [24] [25] [26] , including impairment of the absorptive function, luminal dilation, and reduction of the epithelial height. The genetic disruption of the estrogen receptor Esr2 apparently did not affect the function of this tissue [26] [27] [28] , although this may need to be revised, because a recently described Esr2-null mouse devoid of any transcript downstream of Esr2 exon 3 was found to be infertile [29] . Male fertility is also impaired in mice with a knockout of the aromatase gene Cyp19a1, but in this case, infertility is mainly caused by a defect of germ cell function [30] .
Several studies have demonstrated that long-term treatment of rodents with the antiestrogen fulvestrant, an antagonist of ESR1 and ESR2 receptors, causes morphological changes in the efferent ductules similar to those seen in Esr1 À/À animals, although some species differences are noticeable [31] [32] [33] [34] . On the other hand, treatment with anastrozole, a very potent and selective aromatase inhibitor that inhibits human aromatase with a half maximal inhibitory concentration of 15 nM and has no intrinsic activities [35] , did not affect the morphology of the efferent ductules in boars [36] .
The classical mechanism of fulvestrant action seems to be its interaction with ESR1 and ESR2, inducing a conformational change that impairs the binding of coregulators, thus inhibiting the classical mechanism evoked by estrogen [reviewed in 7, 37 -42] . Furthermore, a reduction in ESR1 expression in the efferent ductules of fulvestrant-treated rats has been shown by immunohistochemical studies [43] . In fact, both fulvestrant [44] [45] [46] [47] and estrogen [44, [48] [49] [50] [51] seem to favor the ubiquitinproteassome-mediated degradation of ESR1. On the other hand, binding of fulvestrant to ESR2 induces distinct conformational changes, which stabilize the receptor [52, 53] .
Recent studies have revealed that the mechanism of fulvestrant action is even more complex. In some tissues, it has been described that the antiestrogen may act as an agonist in the GPER [14, 54, 55] . Interaction of estrogen or fulvestrant with GPER may result in activation of several rapid signaling pathways [56, 57] , and these pathways may modulate several transcription factors, including AP-1 [11] . Finally, after binding to ESR1 and ESR2, fulvestrant may also lead to a protein-protein interaction of ESRs with transcription factors, such as AP-1, SP1, ELK1, CREBBP (CBP), JUN, and STAT5, thus modulating gene transcription [11, 58] .
To gain insight into the possible molecular mechanisms induced by long treatment with fulvestrant in the rat efferent ductules, we have previously performed a microarray analysis of genes affected by the treatment [34] . Besides the expected changes in the expression of genes that codify for ion channels and macromolecule transporters, genes that affect extracellular matrix organization were especially affected by treatment with fulvestrant, and metalloproteinase (MMP) 7 (Mmp7), with a 14-fold increase, was the most affected gene in this category. While MMP7 function in the efferent ductules remains unknown, its overexpression causes male infertility, and MMP7 has been suggested to be important for the maintenance of the integrity of the testicular interstitium [59] . In addition, MMP7 has been detected in spermatozoa, where it may play a role in apoptosis [60] . The dramatic increase in MMP7 expression by fulvestrant treatment appeared surprising to us, because estrogen also increases MMP7 expression in other tissues [61, 62] . Therefore, all possible actions of fulvestrant must be carefully analyzed, because they are certainly not always related to the ability of this compound to block estrogen actions on ESR1 and ESR2.
To better characterize the fulvestrant actions in the efferent ductules, the aim of the present study was to analyze whether the in vivo effects of this antiestrogen on gene expression would be due to the blockade of the estrogen receptors ESR1 and ESR2, or to an agonist effect of fulvestrant, modulating gene transcription through the activation of transcription factors. To help elucidate this question two main strategies were used: 1) comparison of the effects of fulvestrant and the aromatase inhibitor anastrozole on gene and protein expression, by quantitative PCR, Western blot, and immunohistochemistry; and 2) analysis of the fulvestrant effects on the activation of the transcription factors AP-1 and SP1, using electrophoretic mobility shift assay (EMSA).
MATERIALS AND METHODS

Animals and Treatments
Animals. Male Wistar rats born and housed in the Animal Facility at Instituto Nacional de Farmacologia e Biologia Molecular, Universidade Federal de São Paulo (UNIFESP), were maintained on a 12L:12D lighting schedule at 238C, with food and water ad libitum. For all experiments, the efferent ductules were removed from 90-day-old animals. For the EMSA, efferent ductules from both 30-and 90-day-old animals were used. The experimental procedures were conducted according to the Guidelines for Care and Use of Laboratory Animals, and approved by the research ethics committee from UNIFESP. The number of animals is specified in the figures legends.
Treatment with fulvestrant. Thirty-day-old rats were treated once a week for 2 months with corn oil (control group) or with the antiestrogen fulvestrant (10 mg/rat, s.c., Faslodex; AstraZeneca, São Paulo, Brazil), as described previously [32, 34] . This treatment has several effects on the efferent ductule that are also observed in adult Esr1 À/À animals, including luminal dilation, reduced epithelial height, increased lysosomal granule area, and increased microvillus border height, without changes in testicular weight. Similar effects were detected also when treatment with fulvestrant started at an age of 90 days (adult rats) [32] .
Treatment with anastrozole. Sixty-day-old rats were treated daily for 1 month with an oral administration of 1 ml of vehicle (1.5% v/v ethanol/water solution; control group) or 0.1 mg/kg aromatase inhibitor anastrozole (Arimidex; AstraZeneca). This dosage of anastrozole blocked ovulation of adult rats in a single administration, and blocked uterotrophic action of androstenedione in immature rats when administered once a day for 3 days [35] .
Determination of Plasma Testosterone and Estradiol Levels
Previous studies from our laboratory showed that the treatment with fulvestrant did not modify the plasma levels of testosterone and estradiol when compared with 90-day-old control rats [34] . To evaluate the effect of anastrozole on plasma levels of testosterone and estradiol, blood samples were collected from the three to five anastrozole-treated rats and three to five control rats. Hormone assays were performed as previously described [34] . Both assays were previously validated for rat samples, using the standards supplied with the kits for the preparation of the standard curves. Plasma testosterone levels were determined by solid-phase radioimmunoassay with the Coat-A-Count Total Testosterone kit (Diagnostic Products Co., Los Angeles, CA), according to the instructions of the manufacturer. Linearity of the assay was assayed with various sample dilutions, and the rate observed/expected ranged from 90% to 102%. Recovery assayed with three testosterone concentrations ranged from 98% to 103%. The detection limit of this assay was 0.04 ng of testosterone. Low (castrated rats for 15 days) and high (adult 90-day-old rats) testosterone controls were run routinely. The intra-assay variation was 2.1%-2.9%, and interassay variation was 4.2%-5.9%. Plasma estradiol levels were determined by radioimmunoassay with the Double Antibody Estradiol kit (Diagnostic Products Co.), according to the instructions of the manufacturer. Linearity of the assay ranged from 97% to 107%, and recovery ranged from 96% to 99%. The detection limit of this assay was 1.4 pg of estradiol. The intra-assay variation was 0.1%-0.7%, and interassay variation was 0.5%-1.2%. Highestradiol level controls were routinely run with plasma from 90-day-old rats in proestrus (41.64 6 3.78 pg/ml), and the low-estradiol level control was plasma from 15-day-castrated rats (,1.4 pg/ml).
Real-Time Quantitative RT-PCR
The mRNA levels for the following genes were analyzed by quantitative real-time PCR: estrogen receptors Esr1, Esr2, and Gper; androgen receptor (Ar); metalloproteinase 7 (Mmp7); neuronal pentraxin 1 (Nptx1); and secretory phosphoprotein 1 (Spp1). Total RNA was extracted from the efferent ductules of control, fulvestrant, and anastrozole-treated animals with the TRIzol reagent according to the standard protocol [63] ; elimination of any genomic DNA contamination and cDNA synthesis was performed as previously described [64] .
Quantitative PCR. For the quantitative PCR, we used the SYBR Green system (Applied Biosystems, Foster City, CA). The primers (Invitrogen) were designed with the Primer3 program [65] and spanned exon-exon boundaries whenever possible (Table 1) . Beta-actin (Actb) was used as an endogenous control and to normalize cDNA amount and PCR efficiency. Primers for all target genes and beta-actin were designed to have approximately the same amplification efficiency (¼1), which was calculated as previously described [64] . Controls without cDNA or without primers were included in each assay. All cDNAs were diluted 53. An aliquot of 1 ll of the diluted cDNAs was used in the PCR. The cDNAs from each rat were run in triplicate. Samples were run in an ABI PRISM 7500 Sequence Detection System (Applied Biosystems), using default conditions of amplification (508C for 2 min, 958C for 10 min, and 40 cycles of 958C for 15 sec and 608C for 1 min). To confirm specificity of the amplification, dissociation curves were obtained at the end. The average cycle threshold (C T ) was determined with Applied Biosystems software. Data were analyzed by the comparative DDC T method (ABI PRISM User Bulletin #2; Applied Biosystems). The control values were always used as a calibrator in each experiment. Data are expressed as mean 6 SEM of the 2 ÀDDC T from three to six different cDNAs (three to six different animals). The mean 6 SEM of C T values for the endogenous control, Actb, was 16.36 6 0.08 (n ¼ 8). The mean 6 SEM of C T values for the various targets in control groups (n ¼ 3-6) were as follows: Mmp7, 25.57 6 0.43; Esr1, 17.34 6 0.21; Esr2, 28.97 6 2.22; Gper, 26.11 6 0.12; Ar, 20.95 6 0.04; Spp1, 25.76 6 0.26; and Nptx1, 21.42 6 0.11. At the end of the experiments, samples were run in 2% agarose gel electrophoresis to confirm further the absence of nonspecific amplification. The FULVESTRANT AND RAT EFFERENT DUCTULES size of the expected products was compared to a DNA ladder (100-bp ladder; Invitrogen). Whenever necessary, identity of the PCR products was further confirmed by automated DNA sequencing with the DYEnamic ET Terminator Sequencing Kit (GE Healthcare, Piscataway, NJ).
Western Blot Analysis
The efferent ductules from control, fulvestrant-, and anastrozole-treated animals were isolated, frozen immediately in liquid nitrogen, and pulverized in a tissue grinder. Tissues were homogenized in Ultra-Turrax homogenizer in icecold lysis buffer (50 mM Tris [pH 7.5], 1% NP40, 150 mM NaCl, 0.05% sodium deoxycholate, 1 mM EDTA, 0.1% SDS) in the presence of protease inhibitors (1 lg/ml pepstatin, 1 lg/ml leupeptine, 1 lg/ml aprotinin, and 1 mg/ ml PMSF). The lysates were centrifuged at 11 200 3 g for 30 min at 48C. Protein content of the supernatant was determined with the Bio-Rad protein assay and a BSA standard (Bio-Rad Laboratories, Hercules, CA).
Proteins from supernatant (60 lg/lane for ESR1, ESR2, and AR, and 200 lg/lane for MMP7) were subjected to 7.5% (ESR1, ESR2, and AR) or 12% (MMP7) SDS-PAGE. Proteins were electrotransferred overnight (20 V at 48C) to PVDF membranes (0.45-lm pore size, ImmobilonP; Millipore, Bedford, MA). Membranes were blocked for 1 h at room temperature in Tris-buffered saline (TBS; 10 mM Tris, 150 mM NaCl [pH 8.0]) containing 0.2% Tween 20 and 10% nonfat dry milk. The membranes were incubated with the following primary antibodies: anti-ESR1 (M7047; Dako Glostrup, Denmark), 1:1000 dilution in blocking solution, 3 h at room temperature; anti-ESR2 (06-629; Upstate Biotechnology, Millipore), 1:500 dilution, 1 h at room temperature; anti-AR (N-20; Santa Cruz Biotechnology, San Diego, CA), 1:500 dilution, 1 h at room temperature; and anti-MMP7 (Abcam, Cambridge, MA), 1:200 dilution, 16 h at 48C. After washes, the membranes were incubated for 1 h at room temperature with the appropriate secondary antibody: a donkey antirabbit (GE Healthcare) or a goat anti-mouse (Pierce Biotechnology, Rockford, IL) horseradish peroxidase (HRP)-conjugated antibodies, 1:2000 or 1:3000 dilution, respectively. Immunoreactive bands were visualized by autoradiography (Amersham Hyperfilm MP; GE Healthcare) using enhanced chemiluminescence reagent (ECL; PerkinElmer, Boston, MA). Apparent molecular weights of protein bands were determined from molecular weight standards (prestained protein marker, broad range, 6-175 kDa; New England Biolabs, Boston, MA). To quantify protein loadings, membranes were stripped and probed for GAPDH or b-actin (ACTB) expression. For stripping, membranes were washed with TBS-T buffer, incubated with 0.08 M Tris-HCl buffer (pH 6.7) containing 2% SDS and 0.8% b-mercaptoethanol, for 30 min at 558C. After incubation for 2 h in blocking buffer, membranes were incubated with rabbit antibodies against GAPDH (no. 2118; Cell Signaling Technology, Beverly, MA) or ACTB (A5060; Sigma-Aldrich), 1:4000 dilution in TBS-T with 5% BSA. After incubation with the secondary antibody conjugated with HRP, the final product was revealed with ECL reagent and exposed to film for autoradiography as described above.
Band intensities were quantified by densitometric analysis of linear-range autoradiograms by using Epson Expression 1680 scanner (Epson America Inc.) and Quick Scan 2000 WIN software (Helena Laboratories). Results were normalized based on GAPDH or ACTB expression in each sample and plotted (mean 6 SEM) in relation to control, C (¼1). Three to five experiments (two animals for each experiment) were performed.
Immunohistochemistry for Metalloproteinase 7
The efferent ductules from five control animals, three fulvestrant-and three anastrozole-treated animals were dissected free from fat, immersed in Bouin fixative for 16 h, dehydrated, and embedded in paraffin. Longitudinal sections of 5 lm were cut on a microtome and mounted on silanized glass slides.
Immunoperoxidase staining of MMP7 was performed according to a previously described protocol [34] . Briefly, tissue sections were incubated for 15 min at 378C with blocking solution (10% normal rabbit serum) in TBS (20 mM Tris-HCl, 150 mM NaCl, 0.1% BSA [pH 7.4]). Afterwards, they were incubated for 90 min at 378C, with various dilutions (1:30-1:100) of a goat polyclonal antibody raised against a carboxyterminal peptide of human MMP7 (sc-8832; Santa Cruz Biotechnology). The optimal antibody dilution was 1:80. The sections were washed with TBS containing 0.1% Tween 20, incubated with blocking solution for 15 min, and then incubated for 30 min at 378C with a rabbit anti-goat IgG antibody conjugated to HRP (1:250; Calbiochemical, San Diego, CA). Negative control slides were incubated with the primary antibody preadsorbed with a 5-fold higher concentration of the blocking peptide. Sections were visualized with a Nikon E800 microscope (Nikon, Melville, NY), and images were captured with a digital camera and processed with the Image-Pro Express Software program (Media Cybernetics, Silver Spring, MD).
Evaluation of Total [ 35 S]-Methionine Incorporation
The efferent ductules of 6 control animals and 10 fulvestrant-treated animals were removed, dissected free from fat and connective tissues, sliced in pieces (;1 mm 3 ), and maintained in a modified Tyrode solution bubbled with air at 308C [66] . After washes to remove luminal fluid and spermatozoa, total [ 35 S]-methionine incorporation assay was performed according to a previously described protocol [67] [68] [69] . About 150 mg tissue (two animals per experiment, performed in duplicate) were incubated in 2 ml of a Tyrode solution containing 1 mM PMSF, 0.1 mM mixture of aminoacids (except methionine) and 100 lCi [
35 S]-methionine (GE Healthcare), for 4 h at 308C, under constant shaking and aeration. The incubation medium containing released proteins was separated. The tissue was rinsed twice with the Tyrode solution and homogenized in Ultra-turrax homogenizer in ice-cold buffer (10 mM Tris-HCl [pH 7.4], 0.25 M sucrose, 1.5 mM MgCl 2 , 1 mM PMSF, and 0.1% Triton X-100). Incubation medium and homogenized tissue were centrifuged at 100 000 3 g for 30 min at 28C. The supernatant was separated for determination of [ 35 S]-methionine incorporation. A solution of 10% albumin containing 0.5 mM methionine was added to the supernatant, and the proteins were precipitated with 10% (w/v) trichloroacetic acid (TCA) for 16 h at 48C. The pellet was rinsed with the 10% TCA containing 0.5 mM methionine, and solubilized with 0.2 N NaOH for 30 min at 708C. Aliquots of 50 and 100 ll in 5 ml OptiPhase HiSafe-3 scintillation solution (PerkinElmer) were counted in a b counter (LS6000 IC; Beckman Coulter Inc., Palo Alto, CA). Experiments were performed in duplicates, and results were calculated based on the cpm per lg of tissular or released proteins, and expressed as mean 6 SEM. 
Analysis of the Presence of Consensus Sequences for the Potential Binding of Transcription Factors
The localization of the potential promoter region of the genes was analyzed in the Map viewer (National Center for Biotechnology Information [NCBI]; http://www.ncbi.nlm.nih.gov/projects/mapview), expanding 3000 nucleotides from the 5 0 region of the genes. The localization of the potential promoter was confirmed by BLAST (NCBI; http://blast.ncbi.nlm.nih.gov/Blast.cgi). The identity of the transcription factors that could bind to these regions was analyzed by Transcription Elements Search System software (TESS; http:// www.cbil.penn.edu/cgi-bin/tess/tess) [70] .
EMSAs to AP-1 and SP1 Consensus Oligonucleotides
Nuclear protein extracts were obtained from the efferent ductules of 30-dayold untreated rats, and from 90-day-old control and fulvestrant-treated animals, according to standard methods [71, 72] 5 ], 25 mM KCl, 10% glycerol, 0.1 mM EDTA, 1 mM DTT, and 1 mM PMSF), aliquoted, and stored at À758C. Protein concentration was determined according to the method of Bradford [73] , using BSA as a standard. EMSA was performed as previously described [71] . Briefly, consensus AP-1 (5 0 -CGCTTGATGAGTCAGCCGGAA-3 0 ) or SP1 (5 0 -ATTC GATCGGGGCGGGGCGAGC-3 0 ) double-strand oligonucleotide sequences were end-labeled with T4 polynucleotide kinase and c 32 P-ATP (specific activity, 800 Ci/mmol). For DNA-binding reactions, nuclear extracts (15 lg) were incubated in DNA-binding buffer (100 mM Tris-HCl [pH 7.5], 10 mM MgCl 2 , 500 mM NaCl, 5 mM DTT, 5 mM EDTA [pH 8.0], 40% glycerol and 0.01 lg/ll 2.poly(dI-dC)) for 30 min at room temperature. Probe (25 000-35 000 cpm) was added to samples, and tubes were incubated for 45 min at room temperature. Protein-DNA complexes were resolved on nondenaturing 6% polyacrylamide gels buffered with 0.53 Tris/borate/EDTA buffer. Competition studies were performed by incubating samples, before the addition of the 32 P-labeled probes, in the presence of molar excess (50-fold) of unlabeled specific and nonspecific double-stranded oligonucleotide (SP1 as nonspecific competitor for AP-1, and AP-1 as nonspecific competitor for SP1). Gels were dried and exposed to BioMAx MS film with an intensifying screen at À708C for 20-48 h. Autoradiograms were scanned and quantified by Scion Image Analysis (2000-2001; Scion Corp.) for densitometric analysis, and results represent the mean 6 SEM of three (SP1) or five (AP-1) experiments.
Statistical Analysis
Data were expressed as mean 6 SEM. GraphPad Prism software was used for statistical analysis. ANOVA followed by Newman-Keuls test was used for multiple comparisons. Student t-test was used to compare two groups. P values , 0.05 were accepted as significant.
RESULTS
Fulvestrant and Anastrozole Differentially Affect Gene Expression in the Rat Efferent Ductules
We have previously reported that the plasma levels of estradiol and testosterone in 90-day-old rats treated from age 30 to 90 days with fulvestrant were not different from control [34] . Treatment with anastrozole also did not modify the plasma testosterone levels (2.11 6 0.55 ng/ml, n ¼ 5, vs. control 2.61 6 0.77 ng/ml, n ¼ 5), but markedly reduced the plasma levels of estradiol (12.91 6 4.40 pg/ml, n ¼ 3, vs. control 27.66 6 0.92 pg/ml, n ¼ 3; P , 0.05).
The effects of both treatments on the mRNA levels for steroid hormone receptors were evaluated by real-time quantitative PCR (Fig. 1) . Treatment with fulvestrant reduced Esr1 (about 31% compared to control), whereas no significant effects were observed with anastrozole. None of the treatments significantly affected the mRNA levels for Esr2 or Ar, but both significantly (P , 0.05) reduced (about 38% for fulvestrant, and 27% for anastrozole) the mRNA levels of Gper.
We next evaluated the effects of both treatments on the mRNA levels of genes related to organization and remodeling of the extracellular matrix that were affected by the fulvestrant treatment [34] : Nptx1, which encodes the neuronal pentraxin 1; Spp1, which encodes the matrix glycoprotein osteopontin; and Mmp7, which encodes the metalloproteinase 7. The real-time PCR confirmed the results obtained previously in the microarray and Northern blot analysis [34] , showing a significant decrease of Nptx1 gene expression (about 73%), and an increase (about 316%) of Spp1 gene expression after fulvestrant treatment. No effect was noticed with the anastrozole treatment (Fig. 2) . Similarly, a marked increase was observed in Mmp7 gene expression (about 1081%) after fulvestrant treatment, also confirming our previous finding that Mmp7 was the most affected gene [34] . Again, no significant effects were observed with anastrozole treatment (Fig. 2 ).
Fulvestrant and Anastrozole Differentially Affect Protein Expression
The Western blot analysis showed that the expression of ESR1, ESR2, and AR was not significantly affected by the fulvestrant treatment (Fig. 3, A and B) . On the other hand, the treatment with anastrozole caused about 33% reduction in ESR2 expression and about 112% increase in the expression of AR. ESR1 expression was not changed by treatment with the aromatase inhibitor.
MMP7 is secreted as a 28-kDa proenzyme that can be activated by proteolytic removal of the 9-kDa aminoterminal prodomain [74] . The antibody used to detect the protein levels of MMP7 was able to recognize both the pro-MMP7 (28 kDa) and the active protein (19 kDa), because it was directed against an epitope present in the carboxyterminal region of the protein.
Nevertheless, in our Western blot analysis, we were only able FULVESTRANT AND RAT EFFERENT DUCTULES to detect the active form of MMP7 in one out of six independent experiments. Therefore, we only quantified the levels of the 28-kDa precursor of the enzyme. Treatments with fulvestrant and anastrozole did not significantly affect the levels of pro-MMP7 (Fig. 3, A and B) .
Fulvestrant Shifts MMP7 Localization Toward the Apical Membrane of the Epithelial Layer of the Efferent Ductules
In human endometrium, pro-MMP7 is immunolocalized inside epithelial cells, and active MMP7 delineates the plasma membrane of epithelial cells [75] . Considering that the treatments with fulvestrant or anastrozole did not affect pro-MMP7 protein content in the efferent ductules, we examined the effects of both treatments in MMP7 localization in the epithelium of the efferent ductules from 90-day-old animals. As demonstrated in Figure 4 , treatment with fulvestrant drastically shifted MMP7 immunolocalization from the middle (control, Fig. 4A ) toward the apical region of the epithelium (Fig. 4C) . In the efferent ductules of anastozole-treated animals, MMP7 was immunolocalized both in the supranuclear and apical region of epithelial cells (Fig. 4D) . No immunostaining in the epithelium was observed in the negative control incubated with the primary antibody preadsorbed with the respective blocking peptide (Fig. 4B) . Treatment with fulvestrant induced the expected dilation of the lumen and reduction of the epithelial height (Fig. 4C) . On the other hand, treatment with anastrozole did not modify the morphology of the efferent ductules (Fig. 4D) , confirming previous findings from our laboratory [76] .
Fulvestrant Decreases Tissue Protein Content and Increases Protein Release into the Medium
Because fulvestrant drastically affected gene expression and morphology of the efferent ductules, whereas anastrozole had no effect, we next investigated the effect of fulvestrant on the protein content in the tissue and that was released into the medium. Figure 5 shows that the treatment with fulvestrant greatly increased (127.20% 6 (Table 2) . We then performed EMSA to elucidate whether treatment of fulvestrant affects the activity of these transcription factors. Basal levels of AP-1 and SP1 DNA-binding ability were higher in the nuclear extracts from the efferent ductules of 30-day-old than in 90-day-old animals ( Fig. 6, A and B; lanes 1 and 2) . The treatment with fulvestrant for 2 mo (30 to 90 day old) did not significantly affect the DNA-binding activity of AP-1 and SP1 in the efferent ductules.
DISCUSSION
The present study provides evidence that the two strategies to inhibit estrogen action in the efferent ductules-treatment with the antiestrogen fulvestrant or with the aromatase inhibitor anastrozole-had different effects on gene expression in the rat efferent ductules. The mechanisms to inhibit the estrogen action differ importantly between these two treatments. Fulvestrant binds to and promotes degradation of ESR1 [reviewed in 8, 42] , it does not affect plasma estrogen levels [34] , and it profoundly affects morphology and function of the efferent ductules [31] [32] [33] [34] . Treatment with the aromatase inhibitor anastrozole markedly reduces the estrogen levels, and does not significantly affect the morphology and function of the efferent ductules [36, 76 , and present study]. We presently found that only treatment with fulvestrant markedly affected the expression of selected genes, whereas treatment with anastrozole did not cause any dramatic change in gene expression. Similarly, studies with knockout animals have shown alterations in morphology and function of efferent ductules in Esr1 knockout mice [1, 24] , but not in aromatase knockout mice [74] . All together, our data and those from the literature strongly suggest that the presence of a functional ESR1 estrogen receptor is the key factor to maintaining the normal function of this tissue. The presence of a functional   FIG. 4 . Immunohistochemical determination of MMP7 expression in the efferent ductules of control (A), fulvestrant-(C), and anastrozole-(D) treated rats. Cross sections of paraphin-embedded tissues were incubated with anti-MMP7 antibody (1:80 dilution). A) Specific immunolabeling for MMP7 was detected in the supranuclear region of epithelial cells in the efferent ductules of control animals (arrows). B) Negative control, where immunodetection of MMP7 was performed after incubation of the primary antibody with a 5-fold excess of the blocking peptide. C) Note the shift in MMP7 immunolabeling to the apical region of the epithelial cells (arrowheads) in the efferent ductules of fulvestrant-treated rats. D) MMP7 immunolabeling was detected in the supranuclear (arrows) and in the apical (arrowheads) region of the epithelium in the efferent ductules of anastrozole-treated rat. The insets represent higher magnification of the region marked with an asterisk. Representative of three to five independent experiments. Bar ¼ 5 lm. FULVESTRANT AND RAT EFFERENT DUCTULES ESR1 could allow even low concentrations of estradiol or alternative ligands to activate the receptor, and this might explain the main differences between fulvestrant and anastrozole effects.
In rat efferent ductules, ESR1 has been immunolocalized to epithelial ciliated and nonciliated cell nuclei, and ESR2 and AR have been immunolocalized to the nuclei of epithelial, peritubular, and some stromal cells [77] . A change in the balance of these receptors caused by the treatment with fulvestrant could potentially affect the gene expression in the efferent ductules. Our data are in accordance with those of Oliveira et al. [77] showing no changes in ESR2 and AR expression in the efferent ductules after fulvestrant treatment. However, although fulvestrant has been described to promote degradation of estrogen receptors in breast cancer and endometrial cells [45, 46, 78] , and a reduction of ESR1 immunolabeling in the rat efferent ductules [77] , we detected a slight reduction in Esr1 mRNA levels, but no significant changes in the protein expression after treatment with fulvestrant. The [
35 S]-methionine incorporation assays, however, detected a 38% decrease in overall tissue protein content after fulvestrant treatment. The dramatic atrophy of the epithelium of the efferent ductules caused by the treatment with fulvestrant could reflect a general reduction in the protein content of the tissue, making it difficult to interpret specific changes in protein expression. In addition, changes in the protein levels of ESR2 and AR do not seem to be responsible for the significant effect of treatment with fulvestrant on gene expression. This idea is reinforced by the results obtained by the treatment with anastrozole, which did not cause atrophy of the epithelium, but increased AR and decreased ESR2 expression at the protein level. It should be mentioned that the anastrozole treatment did not significantly affect the mRNA levels of Ar and Esr2, corroborating previous reports that mRNA and protein levels are not always correlated [79, 80] . In fact, anastrozole treatment did not modify the mRNA levels of any analyzed genes, except Gper. Since changes in AR and ESR2 expression occurred only at the protein level, we may speculate that treatment with anastrozole may affect posttranscriptional events, but the mechanism of these changes need to be better characterized. Further experimental approaches using specific antibodies against GPER will be important to clarify the expression of this receptor in the efferent ductules. Studies with Gper À/À animals suggest that many commercial antibodies for GPER react with other proteins, making it difficult to detect specific expression of GPER in tissues [reviewed in 81] .
The lack of pronounced effects with anastrozole treatment is in accordance with previous data that show no morphological or transcriptional alterations in aromatase-deficient mice [74] . In addition, reduction of estrogen synthesis in boars delayed epididymal development, but did not affect the morphology of the efferent ductules [36] . As mentioned previously here, although the aromatase inhibitor greatly reduces the estrogen levels, estrogen receptors are not blocked, and could be activated by low remaining levels of the hormone, or by alternative estrogen-independent pathways [reviewed in 8], and these mechanisms could maintain gene expression and function of the efferent ductules. For instance, growth factor signaling leads to activation of kinases that may phosphorylate and activate ESRs or associated coregulators in the absence of ligand [82, 83] . Furthermore, alternative ligands to estrogen receptors may be produced in an aromatase-independent fashion [84, 85] .
In contrast to the anastrozole treatment, which slightly affected protein expression (ESR2 and AR) with no significant changes in mRNA levels, the treatment with fulvestrant greatly affected the gene expression of Nptx1, Spp1, and Mmp7, and levels of Mmp7 mRNA were increased the most. MMP7 is one of the few members of the metalloproteinase family that is expressed in polarized epithelium, where it may play a physiological role during re-epithelialization, apoptosis, and tumorigenesis [86] . Surprisingly, the MMP7 protein levels were not changed with the fulvestrant treatment, as demonstrated by Western blot assays, but we detected a marked change in the localization of the protein from the supranuclear to the apical region of the epithelial cells. In the efferent   FIG. 6 . Analysis of the DNA-binding activity of transcription factors AP-1 (A) and SP1 (B) by eletrophoretic mobility shift assay. Nuclear extracts from the efferent ductules were incubated with the 32 Plabeled oligonucleotides containing the consensus sequence for binding of AP-1 or SP1. Lane 1: nuclear extracts of efferent ductules of 30-day-old rats. Lane 2: nuclear extracts of efferent ductules of 90-day-old control animals. Lane 3: nuclear extracts of efferent ductules of 90-day-old fulvestranttreated rats. Lane 4: competition studies with nuclear extracts from tissues of 30-dayold rats incubated with an excess of the specific unlabeled oligonucleotide (AP-1 in A, and SP1 in B). Lane 5: competition studies with an excess of nonspecific unlabelled oligonucleotide (SP1 in A, and AP-1 in B). Lane 6:
32 P-labeled oligonucleotide alone. Autoradiograms are representative of three (SP1) and five (AP-1) independent experiments. *Statistically significant difference from the other groups (P , 0.05, ANOVA and Newman-Keuls test).
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ductules of anastrozole-treated animals, an increase in the apical immunolocalization of MMP7 was also observed, indicating that not only the blockade of estrogen receptors, but also a decrease of estradiol concentration, may affect MMP7 localization. In human endometrium, a diffuse labeling for pro-MMP7 has been detected to the cytoplasm of epithelial cells, whereas immunolabeling for active MMP7 outlined the epithelial cells [75] . It is therefore possible that the immunolabeling in the apical region of epithelial cells in the efferent ductules corresponds to active MMP7, but the Western blot analysis was not sensitive enough to detect its expression. Apical localization of active MMP7 may play a role in the proliferation of epithelial cells of the efferent ductules, as suggested in polarized Madin-Darby canine kidney cells [87] .
MMP7 possibly plays an important role in tissue remodeling mediated by estrogen in the efferent ductules. Estrogen is important for epithelial development, tissue repair, and remodeling, and stimulates growth factor secretion. Furthermore, the epidermal growth factor receptor (EGFR) is essential for these events [reviewed in 8] . EGFR ligands are expressed as transmembrane precursors, such as the heparin-binding EGF, and can be released from the cell surface by proteases [88] . MMP7 can release EGFR ligands directly or through activation of other proteases [86] . MMP7 can also digest type IV collagen and facilitate migration of the epithelial cells [86] . It is therefore reasonable to propose that the dramatic changes in the epithelium of the efferent ductules caused by treatment with fulvestrant require activation of MMP7/EGFR as a compensatory mechanism to repair the tissue. It is worth mentioning that the treatment with fulvestrant caused a 3-fold increase of Egf gene expression in the efferent ductules [34] .
On the other hand, the [ 35 S]-methionine incorporation assay showed that treatment with fulvestrant reduced the amount of protein associated with the tissue and increased the amount of protein released to the medium. Therefore, one cannot discard the possibility that treatment with fulvestrant, aside from dramatically increasing Mmp7 mRNA levels, may also have increased protein synthesis and secretion. In fact, MMP7 can be found in the lumen of the glandular epithelium of intestine, breast, and prostate [89] , and MMP7 activity has also been detected in human semen, where it may contribute to an increase in apoptosis of spermatozoa [60] and to the infertility observed in fulvestrant-treated animals [31] .
Is Fulvestrant a Direct or Indirect Modulator of Gene Expression In Vivo?
The in vivo treatment with fulvestrant had several effects on gene expression in the rat efferent ductules that are also seen with estrogen. For instance, fulvestrant treatment increased the expression of growth factors Tgfb1 and Tgfb2 by, respectively, 2.5 and 4 times [34] . These growth factors are growth repressors that, like Mmp7, are stimulated by estrogen [90] . These effects of fulvestrant could be explained by two nonexcluding possibilities. First, changes in gene expression would be a consequence of compensatory mechanisms to revert the dramatic effects of a blockade of estrogen action. Several genes related to inflammatory response were altered by fulvestrant treatment [34] , and this may have contributed to changes of several other genes in order to recover homeostasis. Second, although fulvestrant is unable to elicit rapid (nongenomic) actions mediated through classical estrogen receptors, it can act as a potent agonist of ESR1 and ESR2 when the receptors are tethered to the AP-1, SP1, or STAT5 transcription factors [reviewed in 11].
Although not all the genes analyzed in the present study had the identity of the promoter region confirmed, analysis of potential promoter regions encompassing 3000 nt localized 5 0 to the genes showed that all present AP-1 and SP1 sites. Nevertheless, using EMSA, we did not detect changes in the basal levels of AP-1 or SP1 DNA-binding activity in the efferent ductules of fulvestrant-treated animals. Although one cannot exclude completely the possibility that the fulvestrant treatment may directly affect transcription of some genes, we conclude that the significant effects on gene expression by the end of the treatment do not seem to be related with a direct effect of this compound by activating AP-1-or SP1-mediated transcription.
In conclusion, the present study reveals that the two strategies to block the estrogen action in the efferent ductules differentially affected the expression of several target genes. Whereas the effects of fulvestrant were mainly observed at the mRNA level, anastrozole caused relatively minor changes at the protein level. Treatment with fulvestrant may affect gene transcription or mRNA stability, whereas treatment with anastrozole seems to mainly affect posttranscriptional events. The presence of a functional ESR1 receptor seems to be the major difference between the two treatments to explain the markedly distinct effects. At least some of the effects observed with fulvestrant seem to be compensatory to the drastic effects observed after blockade of ESR1-mediated estradiol action in the tissue.
Finally, the overall effects of in vivo treatment with fulvestrant on gene expression may strongly differ from the effects observed in vitro or in less complex models, making it difficult to predict all the possible consequences of antiestrogen administration to patients. This important issue must be taken into consideration during therapies with the different ESR ligands and new antiestrogens.
